Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • May 2, 2007

166_ip_2007-05-02_661450fd-1477-4251-af71-c490268970a1.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Health Care Worldwide

Conference Call, May 2, 2007

Fresenius

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Agenda

  • I. Business Update
  • -Fresenius Group
  • Fresenius Kabi
  • Fresenius ProServe
  • -Fresenius Biotech

II. Financials Q1 2007 / Outlook 2007

Fresenius Group: Excellent Start into 2007

Fresenius Group: All Business Segments Fully on Track to Achieve 2007 Guidance

Fresenius Kabi: Sales Q1 2007 – In Line with Guidance

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 O
i
r
g
a
n
c
G
h
t
r
o
w
S
T
l
l
t
o
a
a
e
s		 4
8
3		 4
6
6		 6
%
S
B
P
d
t
t
r
o
c
e
g
m
e
n
y
u
:
I
f
i
T
h
n
u
s
o
n
e
r
a
p
y		 2
6
2		 2
5
7		 4
%
C
l
i
i
l
N
i
i
t
t
n
c
a
r
o
n
u		 1
9
4		 1
8
0		 1
0
%
T
f
i
T
h
l
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 2
7		 2
9		 5
%
-

Fresenius Kabi: Organic Sales Growth of 6 %

S
l
a		 t
e
s
g
r
o
w		 h
l
i
a
n
a
y
s		 s S
R
i
l
l
e
g
o
n
a
a
e
s		 Q
1
2
0
0
7
€m		 Q
1
2
0
0
6
€m		 G
h
t
r
o
w		 O
i
r
g
a
n
c
G
h
t
r
o
w
in
%		 Q
1
2
0
0
7
s		 l
4
8
3
€
a
e
s
m
:
y oy G
e
r
m
a
n
y		 1
0
6		 1
0
8		 2
%
-		 1
%
-
3
%
-		 E
G
u
r
o
p
e
ex
e
rm
a
ny		 2
3
0		 2
1
9		 5
%		 5
%
1
%
+		 A
i
P
i
f
i
s
a-
a
c
c		 6
9		 9
5		 1
%
7		 2
2
%
L
i
A
i
t
a
n
m
e
r
c
a		 3
0		 3
0		 0
%		 7
%
6
%
+		 4
%
+		 R
W
o		 4
8		 5
0		 4
%
-		 8
%
i
O
r
g
a
n
c
G
h
t
r
o
w		 F
X		 i
A
c
q
u
i
i
t
s
o
n		 R
d
t
e
p
o
r
e		 T
l
l
t
o
a
s
a
e
s		 4
8
3		 4
6
6		 4
%		 6
%

Fresenius Kabi: Excellent EBIT Development

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 C
h
a
n
g
e
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 7
7
5.
1
9
%		 6
8
1
4
6
%		 1
3
%
i
E
B
I
T
b
R
e
g
o
n
y
:
E
u
r
o
p
e
ƒ
E
B
I
T
i
m
a
r
g
n		 7
2
2
1.
4
%		 6
2
1
9.
0
%		 1
6
%
I
i
l
t
t
n
e
r
n
a
o
n
a
ƒ
E
B
I
T
i
m
a
r
g
n		 2
2
1
5.
0
%		 2
1
1
1
%
5.		 5
%
C
C
d
R
&
D
t
t
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e
ƒ		 1
7
-		 1
5
-		 1
3
%
-
N
i
t
e
n
c
o
m
e		 4
2		 2
6		 6
2
%

Fresenius Kabi: 2007 Financial Outlook Confirmed

G
i
d
a
n
c
e
u
O
i
h
t
r
g
a
n
c
r
e
e
n
e
g
r
o
v
u
w		 6
8
%
–
E
B
I
T
i
m
a
r
g
n		 5
1
6
0
1
6
%
–

Fresenius ProServe: Accomplishments

  • Strong sales and earnings development
  • Continued growth strategy in the German hospital market:
  • Acquisition of three hospitals with ~ 500 beds
  • Option exercised to acquire remaining 40 % HUMAINE shares
  • Divestiture of Pharmaplan finalized
  • Pharmatec: agreement to sell business to Bosch group; closing expected end of H1 2007

Fresenius ProServe: Very Good Sales Growth in Q1 2007

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 G
h
t
r
o
w		 O
i
r
g
a
n
c
G
h
t
r
o
w
S
l
a
e
s		 5
2
1		 4
6
7		 9
%		 3
%
S
l
b
D
i
i
i
a
e
s
s
o
n
y
v
:
H
i
l
O
i
t
t
(
H
E
L
I
O
S
)
o
s
p
a
p
e
r
a
o
n
s		 4
3
9		 3
8
3		 1
5
%		 3
%
E
i
i
S
i
f
h
i
l
t
n
g
n
e
e
r
n
g
+
e
r
v
c
e
s
o
r
o
s
p
a
s
(
V
A
M
E
D
P
h
)
t
+
a
r
m
a
e
c		 8
2		 *
9
3		 1
2
%
-		 2
%
O
d
i
k
E
i
i
b
i
t
r
e
r
n
a
e
n
g
n
e
e
r
n
g
u
s
n
e
s
s		 8
7		 *
6
6		 1
8
%		 4
4
%
*
Inc
lu
d
ing
P
ha
lan
rm
ap

Fresenius ProServe: Strong EBIT Development

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 G
h
t
r
o
w
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 3
6
6.
9
%		 3
0
6
3
%		 2
0
%
i
i
i
E
B
I
T
b
D
s
o
n
y
v
:
H
i
l
i
t
t
ƒ
o
s
p
a
o
p
e
r
a
o
n
s
E
B
I
T
i
m
a
r
g
n		 3
2
7.
3
%		 2
7
7
0
%		 1
9
%
E
i
i
S
i
f
h
i
l
t
ƒ
n
g
n
e
e
r
n
g
+
e
r
v
c
e
s
o
r
o
s
p
a
s
E
B
I
T
i
m
a
r
g
n		 5
6.
1
%		 *
5
5
4
%		 -
C
t
t
o
r
p
o
r
a
e
c
o
s
s
ƒ		 1
-		 2
-		 -
*
Inc
lu
d
ing
P
ha
lan
rm
ap

Fresenius ProServe: 2007 Financial Outlook Confirmed

G
i
d
u
a
n
c
e
O
i
r
g
a
n
c
r
e
e
n
e
v
u
h
t
g
r
o
w		 2
3
%
–
E
B
I
T		 1
6
0
1
0
€
7
m
–

Fresenius Biotech: 2007 Accomplishments

  • Provided very encouraging results in malignant ascites from various cancers in March 2007
  • Survival data of the phase II/III study in malignant ascites for both strata to follow in Q2 2007
  • Partnering process for trifunctional antibodies in North America and Japan started

Fresenius Group: Summary

Successful start into the year

All business segments fully on track to achieve 2007 guidance

© Fresenius AG | 18

Group Financials Q1 2007 / Outlook 2007

Fresenius Group: Impact of Currency Translation

Fresenius Group: Profit and Loss Statement

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 C
h
a
l
t
a
c
a
u
t
r
a
e
s		 n
g
e
t
t
c
o
n
s
a
n
t
r
a
e
s		 R
k
e
m
a
r
s
S
l
a
e
s		 2
7
6
7
,		 2
3
8
8
,		 1
6
%
+		 2
2
%
+		 %
i
h
7
t
o
r
g
a
n
c
g
r
o
w
E
B
I
T		 3
8
0		 2
9
1		 3
1
%
+		 3
7
%
+		 S
1
3.
%
E
B
I
T
i
t
7
r
o
n
g
m
a
r
g
n
I
l
t
t
t
n
e
r
e
s
r
e
s
u		 9
5
-		 8
4
-		 1
3
%
-		 2
1
%
-		 I
f
R
C
G
i
i
i
f
t
t
m
p
a
c
o
a
c
q
u
s
o
n
r
o
m
Q
2
0
6
T
a
x
e
s		 1
0
3
-		 6
7
-		 3
6
%
-		 4
2
%
-		 3
6.
1
%
t
t
a
x
r
a
e
N
i
t
e
n
c
o
m
e		 9
3		 6
5		 4
3
%
+		 4
8
%
+		 Q
1
0
6
i
l.
1
1
€
i
t
:
n
c
m
o
n
e-
m
e
e
x
p
e
n
s
e
s
E
P
S
(
f
)
(
€
p
r
e
s		 )
0
6
0		 0
4
3
*		 4
0
%
+		 4
4
%
+
*
A
d
j
d
fo
ha
l
i
te
t
us
r s
re
sp

Fresenius Group: Tax Rate Development

Fresenius Group: Cash Flow

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 C
h
a
n
g
e
Y
Y
o		 R
k
e
m
a
r
s
C
h
f
l
a
s
o
w		 2
8
4		 2
1
8		 3
0
%
+		 S
i
h
t
t
r
o
n
g
e
a
r
n
n
g
s
g
r
o
w
C
h
i
k
i
i
l
t
a
n
g
e
n
w
o
r
n
g
c
a
p
a		 3 3
2
-		 --
O
i
C
h
f
l
t
p
e
r
a
n
g
a
s
o
w		 2
8
7		 1
8
6		 5
4
%
+		 M
i
1
0
4
%
a
r
g
n
:
C
(
)
t
a
p
e
n
e
x		 1
3
2
-		 9
5
-		 3
9
%
-		 I
i
i
h
t
t
t
n
v
e
s
n
g
n
o
g
r
o
w
C
h
f
l
a
s
o
w
(
f
)
b
i
i
i
d
d
i
i
d
d
t
e
o
r
e
a
c
q
s
o
n
s
a
n
e
n
s
u
v		 1
5
5		 9
1		 7
0
%
+
(
)
A
i
i
i
t
t
c
q
u
s
o
n
s
n
e		 6
3
-		 3
2
9
0
-
,		 --
D
i
i
d
d
v
e
n
s		 4
-		 0 --
C
F
h
f
l
r
e
e
a
s
o
w
(
f
i
i
i
d
d
i
i
d
d
)
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 8
8		 3
1
9
9
-
,		 --

Fresenius Group: Debt and Interest Ratios

Fresenius Group: Positive Outlook 2007 Confirmed

Guidance

R
h
t
e
v
e
n
u
e
g
r
o
w		 8
1
0
%
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 –
N
i
h
t
t
e
n
c
o
m
e
g
r
o
w		 2
0
2
5
%
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 –
C
a
p
e
x		 6
0
0
0
0
€
7
m
–
----------------------- -------------------------------------------

Health Care Worldwide

Conference Call, May 2, 2007

Attachments

Fresenius Group: Overview – Calculation of Minority Interest

€
m		 Q
1
2
0
0
7		 F
Y
2
0
0
6
f
E
i
b
d
i
i
i
t
t
t
t
a
r
n
n
g
s
e
o
r
e
a
x
a
n
m
n
o
r
y
n
e
r
e
s		 2
8
5		 1
0
4
9
,
T
a
e
s
x		 1
0
3
-		 4
1
4
-
M
i
i
i
h
f
t
t
t,
t
n
o
r
n
e
r
e
s
e
r
e
o
y
C
F
i
M
d
i
l
i
i
b
b
l
t
t
t
t
t
r
e
s
e
n
s
e
c
a
a
r
e
n
e
n
c
o
m
e
n
o
a
r
a
e
u
u
-
(
)
F
i
6
4
%
t
o
r
e
s
e
n
s
u
~		 8
9
-
8
7
-		 3
0
5
-
2
2
7
-
M
i
i
i
h
l
d
i
F
i
M
d
i
l
C
t
t
t
n
o
r
y
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
e
c
a
a
r
e
-
\$
\$
(
U
S
Q
U
S
d
i
2
0
0
6
1
7
1
0
7
7
:
m
:
m
a
c
c
o
r
n
g
,
C
S
)
F
i
M
d
i
l
's
F
i
i
l
t
t
t
t
o
r
e
s
e
n
s
e
c
a
a
r
e
n
a
n
c
a
a
e
m
e
n
u		 5
-		 1
4
-
M
i
i
i
h
l
d
i
F
i
K
b
i,
t
t
t
n
o
r
y
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
a
-
S
F
i
P
F
i
B
i
h
t
r
e
s
e
n
u
s
r
o
e
r
v
e
r
e
s
e
n
u
s
o
e
c
,		 6
-		 1
9
-
N
i
t
e
n
c
o
m
e		 9
3		 3
3
0

Fresenius Group: Key Figures According to IFRS

i
€
n
m		 Q
1
2
0
0
7
S
G
U
A
A
P		 Q
1
2
0
0
7
S
I
F
R
S
l
a
e
s		 2
7
6
7
,		 2
6
7
7
,
E
B
I
T
3
8
0		 3
9
0
I
l
t
t
t
n
e
r
e
s
r
e
s
u		 9
5
-		 5
9
-
N
i
t
e
n
c
o
m
e		 9
3		 9
9
O
C
f
i
h
l
t
p
e
r
a
n
g
a
s
o
w		 2
8
7		 2
8
8
B
l
h
l
t
t
t
a
a
n
c
e
s
e
e
o
a		 1
5
1
5
9
,		 1
5
1
5
8
,

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.